American Portfolios Advisors Avadel Pharmaceuticals PLC Transaction History
American Portfolios Advisors
- $2.36 Trillion
- Q3 2022
A detailed history of American Portfolios Advisors transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, American Portfolios Advisors holds 500 shares of AVDL stock, worth $6,575. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$6,575% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVDL
# of Institutions
12Shares Held
7.03MCall Options Held
0Put Options Held
0-
Tri Locum Partners LP New York, NY1.19MShares$15.6 Million4.32% of portfolio
-
Knoll Capital Management, LLC Miami, FL600KShares$7.89 Million5.7% of portfolio
-
Knott David M Jr Syosset, NY332KShares$4.37 Million1.53% of portfolio
-
Schulhoff & CO Inc137KShares$1.8 Million0.81% of portfolio
-
1620 Investment Advisors, Inc. Plymouth, MA1KShares$13,1500.01% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $797M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...